Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Short term Debt: 2020

Historic Short term Debt for BridgeBio Pharma (BBIO) over the last 1 years, with Dec 2020 value amounting to $1.5 million.

  • BridgeBio Pharma's Short term Debt was N/A to $3.6 million in Q1 2021 from the same period last year, while for Mar 2021 it was $3.6 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2020, which is N/A change from last year.
  • Per BridgeBio Pharma's latest filing, its Short term Debt stood at $1.5 million for FY2020.
  • In the past 5 years, BridgeBio Pharma's Short term Debt registered a high of $1.5 million during FY2020, and its lowest value of $1.5 million during FY2020.
  • Moreover, its 1-year median value for Short term Debt was $1.5 million (2020), whereas its average is $1.5 million.